Worth reading
60In focus
Scored from 4 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-9000
¥ million (year-on-year change in operating profit)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFiscal year ending March 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales126,257 Millions of yen-2.9%
Operating profit3,567 Millions of yen-71.6%
Ordinary income4,031 Millions of yen-69.5%
Net income3,448 Millions of yen-62.0%
Selling, general and administrative expenses48,055 Millions of yen
Gross Profit Margin
Rate40.9%
Operating profit margin
Rate2.8%
Full-year earnings forecast
Net Sales
121,800 Millions of yen
New drugs, etc. (Japan)
83,500 Millions of yen
New drugs (overseas)
300 Millions of yen
Generic Pharmaceuticals
37,900 Millions of yen
Operating profit
2,000 Millions of yen
Ordinary income
2,300 Millions of yen
Profit attributable to owners of the parent
1,500 Millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in sales of new drugs, etc. (Japan)+¥2,954 million
- Decrease in sales of new drugs (overseas)-¥8,167 million
- Of which, year-on-year decrease in upfront milestone income from KRP-M223-¥8.2 billion
- Increase in generic drug sales+¥1,383 million
- Increase in costs of sales+¥4,083 million
- Increase in SG&A expenses+¥1,087 million
- Increase in R&D expenses+¥1,545 million
- Decrease in selling, general and administrative expenses excluding research and development expenses-¥0.5 billion
New initiatives
- Acquired the development, manufacturing and marketing rights for KRP-126 (BDT272) in Japan, South Korea and Taiwan
- Initiated the confirmatory trial for KRP-DT123
- KRP-114VP advanced to the Phase 3 stage toward expanding Beova's pediatric indication
Key KPIsA metric the company considers important as a management benchmark.
- Beova revenue258 Hundreds of millions of yenYear on year against the same period last year+17.1%
- Lasvic sales73 Hundreds of millions of yenYear on year against the same period last year-7.2%
- Lifnua sales9 Hundreds of millions of yenYear on year against the same period last year+1.6%
- Desalex sales102 Hundreds of millions of yenYear on year against the same period last year+6.5%
- Flutiform sales128 Hundreds of millions of yenYear on year against the same period last year-6.8%
- Pentasa sales123 Hundreds of millions of yenYear on year against the same period last year+1.4%
- Kipres sales22 Hundreds of millions of yenYear on year against the same period last year-37.7%
- Mucodyne sales37 Hundreds of millions of yenYear on year against the same period last year+3.6%
- Milton sales18 Hundreds of millions of yenYear on year against the same period last year-1.8%
- Rubista sales8 Hundreds of millions of yenYear on year against the same period last year-28.6%
- Montelukast tablets "KM" sales114 Hundreds of millions of yenYear on year against the same period last year-4.4%
- Mometasone nasal solution "Kyorin" sales45 Hundreds of millions of yenYear on year against the same period last year+10.0%
Segment results
New drugs, etc. (Japan)
Net Sales
87,113 Millions of yen
Year on year against the same period last year+3.5%
New drugs (overseas)
Net Sales
693 Millions of yen
Year on year against the same period last year-92.2%
Generic Pharmaceuticals
Net Sales
38,451 Millions of yen
Year on year against the same period last year+3.7%
Financial targets
Return on equity
Actual results2.5%
Equity ratio
Actual results72.9%
Number of employees
Number of Employees1,982 people
Change during the period-16 people
Capital expenditures
3,955 Millions of yen
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 126,257 Millions of yen (YoY -2.9%) |
| Operating profit | 3,567 Millions of yen (YoY -71.6%) |
| Ordinary income | 4,031 Millions of yen (YoY -69.5%) |
| Net income | 3,448 Millions of yen (YoY -62.0%) |
| Gross Profit Margin | Rate 40.9% / Year-on-year change (points) Not disclosed |
| Operating profit margin | Rate 2.8% / Year-on-year change (points) Not disclosed |
| Selling, general and administrative expenses | 48,055 Millions of yen |
| Full-year earnings forecast | Net Sales 121,800 Millions of yen / New drugs, etc. (Japan) 83,500 Millions of yen / New drugs (overseas) 300 Millions of yen / Generic Pharmaceuticals 37,900 Millions of yen / Operating profit 2,000 Millions of yen / Ordinary income 2,300 Millions of yen / Profit attributable to owners of the parent 1,500 Millions of yen |
| Segment results | New drugs, etc. (Japan) Net Sales 87,113 Millions of yen / Year on year against the same period last year +3.5% / New drugs (overseas) Net Sales 693 Millions of yen / Year on year against the same period last year -92.2% / Generic Pharmaceuticals Net Sales 38,451 Millions of yen / Year on year against the same period last year +3.7% |
| Breakdown of Factors Affecting the Change | Factors Increase in sales of new drugs, etc. (Japan) / Amount +¥2,954 million, Factors Decrease in sales of new drugs (overseas) / Amount -¥8,167 million, Factors Of which, year-on-year decrease in upfront milestone income from KRP-M223 / Amount -¥8.2 billion, Factors Increase in generic drug sales / Amount +¥1,383 million, Factors Increase in costs of sales / Amount +¥4,083 million, Factors Increase in SG&A expenses / Amount +¥1,087 million, Factors Increase in R&D expenses / Amount +¥1,545 million, Factors Decrease in selling, general and administrative expenses excluding research and development expenses / Amount -¥0.5 billion |
| Key KPIs | Indicator name Beova revenue / Value 258 Hundreds of millions of yen / Year on year against the same period last year +17.1%, Indicator name Lasvic sales / Value 73 Hundreds of millions of yen / Year on year against the same period last year -7.2%, Indicator name Lifnua sales / Value 9 Hundreds of millions of yen / Year on year against the same period last year +1.6%, Indicator name Desalex sales / Value 102 Hundreds of millions of yen / Year on year against the same period last year +6.5%, Indicator name Flutiform sales / Value 128 Hundreds of millions of yen / Year on year against the same period last year -6.8%, Indicator name Pentasa sales / Value 123 Hundreds of millions of yen / Year on year against the same period last year +1.4%, Indicator name Kipres sales / Value 22 Hundreds of millions of yen / Year on year against the same period last year -37.7%, Indicator name Mucodyne sales / Value 37 Hundreds of millions of yen / Year on year against the same period last year +3.6%, Indicator name Milton sales / Value 18 Hundreds of millions of yen / Year on year against the same period last year -1.8%, Indicator name Rubista sales / Value 8 Hundreds of millions of yen / Year on year against the same period last year -28.6%, Indicator name Montelukast tablets "KM" sales / Value 114 Hundreds of millions of yen / Year on year against the same period last year -4.4%, Indicator name Mometasone nasal solution "Kyorin" sales / Value 45 Hundreds of millions of yen / Year on year against the same period last year +10.0% |
| Number of employees | Number of Employees 1,982 people / Change during the period -16 people |
| Financial targets | Return on equity Actual results 2.5% / Equity ratio Actual results 72.9% |
| Capital expenditures | 3,955 Millions of yen |
| New initiatives | Acquired the development, manufacturing and marketing rights for KRP-126 (BDT272) in Japan, South Korea and Taiwan, Initiated the confirmatory trial for KRP-DT123, KRP-114VP advanced to the Phase 3 stage toward expanding Beova's pediatric indication |
Items this document does not state (14)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, profits were depressed by the year-on-year decrease in upfront milestone income related to KRP-M223, an out-licensed product overseas, drug price revisions, a higher cost-of-sales ratio due to increased generic drug sales, and higher research and development expenses resulting from upfront milestone payments for in-licensed products and the Phase 3 trial costs for KRP-R120. For the fiscal year ending March 2027, lower revenue due to lower Desalex sales and drug price revisions is expected to be the primary factor behind the decline in operating profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.